International Journal of Pediatric Endocrinology volume , Article number: 15 Cite this article. Metrics details. Children with Idiopathic Short Stature do not attain a normal adult height. The improvement of adult height with treatment with recombinant human growth hormone rhGH , at doses of 0.
The benefit obtained seems dose dependent and benefits of 7. The topic has remained controversial. The objective was to conduct a retrospective analysis of our experience with children with ISS treated with 0.
Eighty eight of our children 68 males and 20 females attained an adult height or near adult height of In the analysis of the subgroups, the adult height and adult height gain of children with non-familial short stature were significantly higher than of familial short stature.
No difference was found in the cohorts with normal or delayed puberty in any of the subgroups, except between the non-familial short stature and familial short stature puberty cohorts. This has implications for the interpretation of the benefit of treatment in studies where the number of children with familial short stature in the controls or treated subjects is not known. The treatment was safe. There were no significant adverse events. The IGF-1 values were essentially within the levels expected for the stages of puberty.
Our experience was quite positive with normalization of the heights and growth of the children during childhood and the attainment of normal adult heights, the main two aims of treatment. Children with idiopathic short stature ISS do not attain a normal adult height. In the three randomized controlled studies Cochran Central Register Control Trials , the adult height of the controls was In an additional 6 non-randomized controlled studies the adult height of the controls ranged between Growth hormone treatment significantly improves the growth velocity and the adult height of children with ISS [ 10 β 13 ] and is considered safe [ 14 β 16 ].
